Doxycycline sclerotherapy for pediatric head and neck macrocystic lymphatic malformations

A case series and review of the literature

Nausheen Jamal, Sameer Ahmed, Todd S. Miller, John P. Bent, Allan L. Brook, Sanjay Parikh, Ashish Ankola

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: (a) To evaluate the efficacy of doxycycline as a percutaneous sclerotherapy agent in pediatric head and neck macrocystic lymphatic malformations (LM) and (b) to review the literature with regard to recent developments in the treatment of lymphatic malformations using sclerotherapy. Methods: We reviewed the medical records and imaging studies of all patients who underwent percutaneous sclerotherapy of macrocystic LM of the head and neck at our institution between June 2005 and May 2010. All studies were reviewed and procedures performed by a single interventional neuroradiologist using computed tomography (CT) guidance. LM were individually cannulated, the contents aspirated, and then injected with doxycycline at concentrations of 10-20. mg/ml. Response to sclerotherapy was determined clinically. Results: Seven patients underwent a total of eight sclerotherapy treatments during the study period. Of the six patients with appropriate follow-up, 67% have experienced complete or near-complete clinical resolution of their LM (1243 days mean follow-up), while 33% have developed recurrent swelling after an initial response following a single doxycycline injection (53 days mean follow-up). Conclusions: Our institutional results, in combination with recently published findings, support the moderate efficacy and excellent safety profile of percutaneous doxycycline sclerotherapy for macrocystic lymphatic malformations.

Original languageEnglish (US)
Pages (from-to)1127-1131
Number of pages5
JournalInternational Journal of Pediatric Otorhinolaryngology
Volume76
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Sclerotherapy
Doxycycline
Neck
Head
Pediatrics
Diagnostic Imaging
Medical Records
Tomography
Safety
Injections
Therapeutics

Keywords

  • Doxycycline
  • Lymphangioma
  • Lymphatic malformation
  • Sclerotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Pediatrics, Perinatology, and Child Health

Cite this

Doxycycline sclerotherapy for pediatric head and neck macrocystic lymphatic malformations : A case series and review of the literature. / Jamal, Nausheen; Ahmed, Sameer; Miller, Todd S.; Bent, John P.; Brook, Allan L.; Parikh, Sanjay; Ankola, Ashish.

In: International Journal of Pediatric Otorhinolaryngology, Vol. 76, No. 8, 08.2012, p. 1127-1131.

Research output: Contribution to journalArticle

@article{65ef86bb383143ffa34d47c80fb18a0c,
title = "Doxycycline sclerotherapy for pediatric head and neck macrocystic lymphatic malformations: A case series and review of the literature",
abstract = "Objective: (a) To evaluate the efficacy of doxycycline as a percutaneous sclerotherapy agent in pediatric head and neck macrocystic lymphatic malformations (LM) and (b) to review the literature with regard to recent developments in the treatment of lymphatic malformations using sclerotherapy. Methods: We reviewed the medical records and imaging studies of all patients who underwent percutaneous sclerotherapy of macrocystic LM of the head and neck at our institution between June 2005 and May 2010. All studies were reviewed and procedures performed by a single interventional neuroradiologist using computed tomography (CT) guidance. LM were individually cannulated, the contents aspirated, and then injected with doxycycline at concentrations of 10-20. mg/ml. Response to sclerotherapy was determined clinically. Results: Seven patients underwent a total of eight sclerotherapy treatments during the study period. Of the six patients with appropriate follow-up, 67{\%} have experienced complete or near-complete clinical resolution of their LM (1243 days mean follow-up), while 33{\%} have developed recurrent swelling after an initial response following a single doxycycline injection (53 days mean follow-up). Conclusions: Our institutional results, in combination with recently published findings, support the moderate efficacy and excellent safety profile of percutaneous doxycycline sclerotherapy for macrocystic lymphatic malformations.",
keywords = "Doxycycline, Lymphangioma, Lymphatic malformation, Sclerotherapy",
author = "Nausheen Jamal and Sameer Ahmed and Miller, {Todd S.} and Bent, {John P.} and Brook, {Allan L.} and Sanjay Parikh and Ashish Ankola",
year = "2012",
month = "8",
doi = "10.1016/j.ijporl.2012.04.015",
language = "English (US)",
volume = "76",
pages = "1127--1131",
journal = "International Journal of Pediatric Otorhinolaryngology",
issn = "0165-5876",
publisher = "Elsevier Ireland Ltd",
number = "8",

}

TY - JOUR

T1 - Doxycycline sclerotherapy for pediatric head and neck macrocystic lymphatic malformations

T2 - A case series and review of the literature

AU - Jamal, Nausheen

AU - Ahmed, Sameer

AU - Miller, Todd S.

AU - Bent, John P.

AU - Brook, Allan L.

AU - Parikh, Sanjay

AU - Ankola, Ashish

PY - 2012/8

Y1 - 2012/8

N2 - Objective: (a) To evaluate the efficacy of doxycycline as a percutaneous sclerotherapy agent in pediatric head and neck macrocystic lymphatic malformations (LM) and (b) to review the literature with regard to recent developments in the treatment of lymphatic malformations using sclerotherapy. Methods: We reviewed the medical records and imaging studies of all patients who underwent percutaneous sclerotherapy of macrocystic LM of the head and neck at our institution between June 2005 and May 2010. All studies were reviewed and procedures performed by a single interventional neuroradiologist using computed tomography (CT) guidance. LM were individually cannulated, the contents aspirated, and then injected with doxycycline at concentrations of 10-20. mg/ml. Response to sclerotherapy was determined clinically. Results: Seven patients underwent a total of eight sclerotherapy treatments during the study period. Of the six patients with appropriate follow-up, 67% have experienced complete or near-complete clinical resolution of their LM (1243 days mean follow-up), while 33% have developed recurrent swelling after an initial response following a single doxycycline injection (53 days mean follow-up). Conclusions: Our institutional results, in combination with recently published findings, support the moderate efficacy and excellent safety profile of percutaneous doxycycline sclerotherapy for macrocystic lymphatic malformations.

AB - Objective: (a) To evaluate the efficacy of doxycycline as a percutaneous sclerotherapy agent in pediatric head and neck macrocystic lymphatic malformations (LM) and (b) to review the literature with regard to recent developments in the treatment of lymphatic malformations using sclerotherapy. Methods: We reviewed the medical records and imaging studies of all patients who underwent percutaneous sclerotherapy of macrocystic LM of the head and neck at our institution between June 2005 and May 2010. All studies were reviewed and procedures performed by a single interventional neuroradiologist using computed tomography (CT) guidance. LM were individually cannulated, the contents aspirated, and then injected with doxycycline at concentrations of 10-20. mg/ml. Response to sclerotherapy was determined clinically. Results: Seven patients underwent a total of eight sclerotherapy treatments during the study period. Of the six patients with appropriate follow-up, 67% have experienced complete or near-complete clinical resolution of their LM (1243 days mean follow-up), while 33% have developed recurrent swelling after an initial response following a single doxycycline injection (53 days mean follow-up). Conclusions: Our institutional results, in combination with recently published findings, support the moderate efficacy and excellent safety profile of percutaneous doxycycline sclerotherapy for macrocystic lymphatic malformations.

KW - Doxycycline

KW - Lymphangioma

KW - Lymphatic malformation

KW - Sclerotherapy

UR - http://www.scopus.com/inward/record.url?scp=84862758823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862758823&partnerID=8YFLogxK

U2 - 10.1016/j.ijporl.2012.04.015

DO - 10.1016/j.ijporl.2012.04.015

M3 - Article

VL - 76

SP - 1127

EP - 1131

JO - International Journal of Pediatric Otorhinolaryngology

JF - International Journal of Pediatric Otorhinolaryngology

SN - 0165-5876

IS - 8

ER -